DOCSLIB.ORG

Microgram Journal, Vol 2, Number 1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Microgram Journal, Vol 2, Number 1 Washington, D. C. Office of Science and Education Vol.II,No.1 Division of Laboratory Operations January 1969 INDEXISSUE CORRECTION 11 "Structure Elucidation of 'LBJ' , by Sander W. Bellman, John W. Turczan, James Heagy and Ted M. Hopes, Micro­ Gram .!., 3, 6-13 (Dec. 1968) Page 7, third and fourth sentences under Discussion: Change to read: "The melting point of the acid moiety found in step (g) was 148-150°c., compared to the litera­ ture, v~lue of 151°c for the melting point of benzilic acid (2); thus the benzilic acid melting point gives support to the proposed structure for 'LBJ'. Spectral evidence also supports the proposed structure". MICRO-GRAMREVISION Please re-number the pages of your copies of Micro-Gram, Volume I. Re-number pages bearing printing only. Vol­ ume I will then be numbered from page 1, the front page of issue No. 1, through page 189 the last page of issue No. 12. To help with this task, pages contained within each issue are as follows: Issue Number Page Through 1 1 8 2 9 29 3 30 32 4 33 66 5 67 79 6 80 97 7 98 120 8 121 128 9 129 136 10 137 157 11 158 170 12 171 189 CAUTION: Use of this publication should be restricted to forensic analysts or others having a legitimate need for this material. From the Archive Library of Erowid Center http://erowid.org/library/periodicals/microgram -2- CANNABIS ,·,-...__/' Attached is a copy of 11A Short Rapid Method for the Identification of Cannabis." The method was developed by Mro H.D. Beckstead and Dr. W.N. French of the Pharmaceutical Chemistry Division, Food and Druf Directorate Research Laboratories, ottawa, Canada. It was furnished ,to ~ by Mr. R.Ao Graham of the Research Laboratories, who wri tAs that it has been in use for some time in their field laboratories. LSD -BNDDagents in the East recently purchased LSD tablets which were snall, polished and were consistent in size. These have been obtai.ned in blue, red and aqua, or green, in color. It is belj_eved that colors are used by the clandestine operator to identify batches. Other LSD tablets were also recently purchased by BNDDagents:, an:i were new to our laboratory. These tablets were round, biconvex, 'approxi.mately 7/16 inch in diameter, and were white, speckled with red, green:, blue and purple fragments embedded in the t::i.bleto Average LSD content was 388 micror,rans pe~ tableto LSD continues to come in many colors. Recent powder has been lavender colored. Tablets have been charcoal grey, raspberry, pm-ple; p:$.:nkand blue, among other colors. Recently a poorly made, pink ISD tablet A.ppeared in various parts of the country bearing the so-called peace s:J111bolas a monogram. HAWAIIANBABY WOOD ROSE (Argyreia nervosa) BNDDagents in the East recently purchased capsules conta:i.nine a light brown powder alledged to be mescaline. Analysis showed it to be Arfo'oeia nervosa. It is reportedly available in pound quantities at $2 00 per pound. METHYLPHBNIDATEHCl Hethylphenidate h;itd.rochloride (Ritalin HCl), as well as the parent compound and :i.ts other salts, became a controlled drug mder the 11DACA" 1J:1endmentson April 6, 1969. PH'RNCYCLIDINE Phencyclidine arrl its salts became a controlled drug· under the NDACA" amendments on April 6, 1969. From the Archive Library of Erowid Center http://erowid.org/library/periodicals/microgram -3- PHENCYCLIDINEBASE Our Research and Special Testing Laboratory recently identified phencyclidine base submitted by a West Coast police department. The drug was reportedly involved in a non-fatal shooting, in which one member of the "Hell's Angels" shot another member fifteen times with a 45-caliber weapon. The compound is known as "Dead on Arrival" or "Dust of Angels," and may be known as "DOA". It is reportedly used by placing about fifty milligrams on a cigarette. The sample submitted was a white powder in a plastic bag, with a paper marked "1 Gram $125.00, 20 cigarettes ••. " Joseph Koles, BNDDforensic chemist, reports that the melting point of the base is 46 to 46.5 degrees. For the hydrochloride, the melt­ ing point ranges from 222 to 228 degrees C. (1) The base must be dis­ solved in a little acid before making the crystal test, according to Koles. Albert R. Sperling, Ph.D., BNDDResearch chemist, reports that the base is chloroform soluble and the ultraviolet spectrum and color tests are the same as for the hydrochloride salt. (2, 3) Dr. Sperling furnished the attached infra-red spectrogram, obtained from a film between salt plates. A potassium bromide disc of the powdered free bases gives an identical spectrum. Ref: 1. The Merck Index, 8th Edition, page 806 2. Microgram, Vol. I, No. 3, 30-32 (Jan. 1968) 3. Microgram, Vol. I, No. 12, 173 and 184-188 (Dec. 1968) FORENSICCHEMIST'S SEMINAR The next chemist's seminar is schedule for May 19-23, 1969, in Washington, D.C. For application forms or information about the seminars write to: Director Bureau of Narcotics and Dangerous Drugs Washington, D. C. 20537 ATTN: John Doyle, Chief Special Programs Division Office of Training From the Archive Library of Erowid Center http://erowid.org/library/periodicals/microgram -4- A. SHORTRAPID METHOD FOR THEIDENTIFICATION OFCANNABIS H.D. Beckstead and W.N. French Food and Drug Directorate Research Laboratories Otta-wa, Canada Definition: This is a rapid, simple and.reliable method for the identifi­ cation of cannabis (marihuana) in exhibits. The procedure permits the differentiation of cannabis from other plant materials such as oregano, khat, ragweed, etc. which frequently are used as diluents. Principle: The sample is subjected to visual macroscopic and microscopic examination as well as to the Duquenois colour test and acid chloral test. The identity of cannabis is confirmed by a thin­ layer chromatographic test on a g-hexane extract of the sample material (Note 1). Additional evidence of identity may be acquired by the use of gas chromatography. ~pparatus: 1. Lowpower microscope. 2. TU:: equipment. 3. Impregnation chamber (Note 2). 4. Gas-Liquid chromatograph equipped with flame ionization detector (Note 3). Reference 1. 11ixed hashish resin standard (10 mg per ml !!-hexane) (Note 4). Materials: 2. Cannabidiol (5 mg per ml g-hexane) (Note 4). 3. Cannabinol (5 mg per ml g-hexane) (Note 4). Reagents 1. Acid chloral reagent - Dissolve 10 g chloral hydrate in 100 and ml of 20% v/v aqueous HCl. Materials: 2. Duquenois reagent - Dissolve 2 g vanillin in 100 ml of 95% ethanol. This stock solution keeps indefinitely if refriger­ ated. Immediately before use, mix 1 ml of solution with 3 drops of acetaldehyde. From the Archive Library of Erowid Center http://erowid.org/library/periodicals/microgram -5- 3. Thin-Layer Chromatoplates (a) Preparation of layers - Using standard thin-layer chroma­ tographic apparatus, coat S x 8 inch glass plates to a thickness of 0.50 rrunusing a slurry of 55 g of Kieselguhr G, 100 ml Hi and 10 ml of 1% w/v aqueous sodium carboxy­ methylce11ulose for 5 plates (Hotc 5). Allow layers to air dry in a dust-free atmosphere. activation is not necessary. (b) Impregnation with N-rnethylformamide - Mark the chromato­ plate with a sharp stylus to indicate the spotting positions with 15 cm solvent-developing distance. Immerse the plate vertically, with spotting positions uppermost, in a solution of 100 ml of N-methylformamide and 325 ml of acetone (Note 2). ~fter 5 minutes, remove the plate, allowing to drain, and air dry for 5 minutes. The impregnated plate is not susceptible to moisture pick- up, even over-night, so the sample need not be spotted immediately (Note 6). 4. Jhin-La.yer Chromatographic Solvent - Shake 100 ml of cyclo­ hexane with 10 ml of' N""!nethylformamide. Use the upper layer (Note 7). 5. Thin-Layer Chromatographic Detection Reagent - DiS$Olve 200 mg Fa.st Blue Salt B or Fast Blue Salt RR in 100 ml 50% ethanol. This reagent must be prepared fresh each day. Procedure: 1. Visual Examination of Sample Material (a) ;1acroscopic - This examination is used only to establish the presence of plant material in the exhibit. The colour, odour and form of cannabis is usually quite distinctive and different from materials used as diluents or substitutes. Examine the material under a hand lens or low power stereoscopic microscope, and separate sus­ pected marihuana plant parts from diluents. From the Archive Library of Erowid Center http://erowid.org/library/periodicals/microgram -6- {b) 1'1icroscopic - This examination is used to observe the detailed physical characteristics of the plant material using a microscope. The cannabis plant has typical cystolith hairs on the stems and underside of leaves. Extracts of cannabis (i.e. cannabis resin) usually contain considerable amounts of plant material including cystolith hairs. The latter may be readily detected by mixing a small quantity of resin with n-hexane (as in 3(b) below), transferring a drop of suspension to a microscopic slide and observing under the microscope when solvent evaporates. 2. Acid Chloral Test This test is used to detect the presence of carl:>onate deposits on the suspected plant material. Add a small drop of acid chloral reagent to a portion of the suspected plant material while observing under the microscope. Note any effervescence which may occur. The cystolith hair of cannabis contains a calcium carl:>onate deposit which liberates on treatment with co2 acid giving rise to effervescence. 3. Preparation of Sample (a) Green Plant 11aterial - Place approximately 50 mg of sample in a 10 x 75 mmtest tube, and add sufficient n~hexa.ne (0.5 ml) to just cover the sample.
Load more

Recommended publications
  • Analysis of Drugs Manual September 2019
    Drug Enforcement Administration Office of Forensic Sciences Analysis of Drugs Manual September 2019 Date Posted: 10/23/2019 Analysis of Drugs Manual Revision: 4 Issue Date: September 5, 2019 Effective Date: September 9, 2019 Approved By: Nelson A. Santos Table of Contents CHAPTER 1 – QUALITY ASSURANCE ......................................................................... 3 CHAPTER 2 – EVIDENCE ANALYSIS ......................................................................... 93 CHAPTER 3 – FIELD ASSISTANCE .......................................................................... 165 CHAPTER 4 – FINGERPRINT AND SPECIAL PROGRAMS ..................................... 179 Appendix 1A – Definitions ........................................................................................... 202 Appendix 1B – Acronyms and Abbreviations .............................................................. 211 Appendix 1C – Instrument Maintenance Schedule ..................................................... 218 Appendix 1D – Color Test Reagent Preparation and Procedures ............................... 224 Appendix 1E – Crystal and Precipitate Test Reagent Preparation and Procedures .... 241 Appendix 1F – Thin Layer Chromatography................................................................ 250 Appendix 1G – Qualitative Method Modifications ........................................................ 254 Appendix 1H – Analytical Supplies and Services ........................................................ 256 Appendix 2A – Random Sampling Procedures
    [Show full text]
  • Index Vol. 12-15
    353 INDEX VOL. 12-15 Die Stichworte des Sachregisters sind in der jeweiligen Sprache der einzelnen Beitrage aufgefiihrt. Les termes repris dans la Table des matieres sont donnes selon la langue dans laquelle l'ouvrage est ecrit. The references of the Subject Index are given in the language of the respective contribution. 14 AAG (Alpha-acid glycoprotein) 120 14 Adenosine 108 12 Abortion 151 12 Adenosine-phosphate 311 13 Abscisin 12, 46, 66 13 Adenosine-5'-phosphosulfate 148 14 Absorbierbarkeit 317 13 Adenosine triphosphate 358 14 Absorption 309, 350 15 S-Adenosylmethionine 261 13 Absorption of drugs 139 13 Adipaenin (Spasmolytin) 318 14 - 15 12 Adrenal atrophy 96 14 Absorptionsgeschwindigkeit 300, 306 14 - 163, 164 14 Absorptionsquote 324 13 Adrenal gland 362 14 ACAI (Anticorticocatabolic activity in­ 12 Adrenalin(e) 319 dex) 145 14 - 209, 210 12 Acalo 197 15 - 161 13 Aceclidine (3-Acetoxyquinuclidine) 307, 13 {i-Adrenergic blockers 119 308, 310, 311, 330, 332 13 Adrenergic-blocking activity 56 13 Acedapsone 193,195,197 14 O(-Adrenergic blocking drugs 36, 37, 43 13 Aceperone (Acetabutone) 121 14 {i-Adrenergic blocking drugs 38 12 Acepromazin (Plegizil) 200 14 Adrenergic drugs 90 15 Acetanilid 156 12 Adrenocorticosteroids 14, 30 15 Acetazolamide 219 12 Adrenocorticotropic hormone (ACTH) 13 Acetoacetyl-coenzyme A 258 16,30,155 12 Acetohexamide 16 14 - 149,153,163,165,167,171 15 1-Acetoxy-8-aminooctahydroindolizin 15 Adrenocorticotropin (ACTH) 216 (Slaframin) 168 14 Adrenosterone 153 13 4-Acetoxy-1-azabicyclo(3, 2, 2)-nonane 12 Adreson 252
    [Show full text]
  • Cannabigerol Is a Potential Therapeutic Agent in a Novel Combined Therapy for Glioblastoma
    cells Article Cannabigerol Is a Potential Therapeutic Agent in a Novel Combined Therapy for Glioblastoma Tamara T. Lah 1,2,3,*, Metka Novak 1, Milagros A. Pena Almidon 4, Oliviero Marinelli 4 , Barbara Žvar Baškoviˇc 1, Bernarda Majc 1,3, Mateja Mlinar 1, Roman Bošnjak 5, Barbara Breznik 1 , Roby Zomer 6 and Massimo Nabissi 4 1 Department of Genetic Toxicology and Cancer Biology, National Institute of Biology, 1000 Ljubljana, Slovenia; [email protected] (M.N.); [email protected] (B.Ž.B.); [email protected] (B.M.); [email protected] (M.M.); [email protected] (B.B.) 2 Faculty of Chemistry and Chemical Technology, University of Ljubljana, 1000 Ljubljana, Slovenia 3 Jožef Stefan International Postgraduate School, 1000 Ljubljana, Slovenia 4 School of Pharmacy, Experimental Medicine Section, University of Camerino, 62032 Camerino, Italy; [email protected] (M.A.P.A.); [email protected] (O.M.); [email protected] (M.N.) 5 Department of Neurosurgery, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia; [email protected] 6 MGC Pharmaceuticals d.o.o., 1000 Ljubljana, Slovenia; [email protected] * Correspondence: [email protected]; Tel.: +386-41-651-629 Simple Summary: Among primary brain tumours, glioblastoma is the most aggressive. As early relapses are unavoidable despite standard-of-care treatment, the cannabinoids delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) alone or in combination have been suggested as a combined treatment strategy for glioblastomas. However, the known psychoactive effects of THC hamper its medical applications in these patients with potential cognitive impairment due to the progression of the Citation: Lah, T.T.; Novak, M.; Pena Almidon, M.A.; Marinelli, O.; disease.
    [Show full text]
  • A Dissertation Entitled Uncovering Cannabinoid Signaling in C. Elegans
    A Dissertation Entitled Uncovering Cannabinoid Signaling in C. elegans: A New Platform to Study the Effects of Medicinal Cannabis By Mitchell Duane Oakes Submitted to the Graduate Faculty as partial fulfillment of the requirements for the Doctor of Philosophy Degree in Biology ________________________________________ Dr. Richard Komuniecki, Committee Chair _______________________________________ Dr. Bruce Bamber, Committee Member ________________________________________ Dr. Patricia Komuniecki, Committee Member ________________________________________ Dr. Robert Steven, Committee Member ________________________________________ Dr. Ajith Karunarathne, Committee Member ________________________________________ Dr. Jianyang Du, Committee Member ________________________________________ Dr. Amanda Bryant-Friedrich, Dean College of Graduate Studies The University of Toledo August 2018 Copyright 2018, Mitchell Duane Oakes This document is copyrighted material. Under copyright law, no parts of this document may be reproduced without the expressed permission of the author. An Abstract of Uncovering Cannabinoid Signaling in C. elegans: A New Platform to Study the Effects of Medical Cannabis By Mitchell Duane Oakes Submitted to the Graduate Faculty as partial fulfillment of the requirements for the Doctor of Philosophy Degree in Biology The University of Toledo August 2018 Cannabis or marijuana, a popular recreational drug, alters sensory perception and exerts a range of medicinal benefits. The present study demonstrates that C. elegans exposed to
    [Show full text]
  • Adverse Reactions to Hallucinogenic Drugs. 1Rnstttutton National Test
    DOCUMENT RESUME ED 034 696 SE 007 743 AUTROP Meyer, Roger E. , Fd. TITLE Adverse Reactions to Hallucinogenic Drugs. 1rNSTTTUTTON National Test. of Mental Health (DHEW), Bethesda, Md. PUB DATP Sep 67 NOTE 118p.; Conference held at the National Institute of Mental Health, Chevy Chase, Maryland, September 29, 1967 AVATLABLE FROM Superintendent of Documents, Government Printing Office, Washington, D. C. 20402 ($1.25). FDPS PRICE FDPS Price MFc0.50 HC Not Available from EDRS. DESCPTPTOPS Conference Reports, *Drug Abuse, Health Education, *Lysergic Acid Diethylamide, *Medical Research, *Mental Health IDENTIFIEPS Hallucinogenic Drugs ABSTPACT This reports a conference of psychologists, psychiatrists, geneticists and others concerned with the biological and psychological effects of lysergic acid diethylamide and other hallucinogenic drugs. Clinical data are presented on adverse drug reactions. The difficulty of determining the causes of adverse reactions is discussed, as are different methods of therapy. Data are also presented on the psychological and physiolcgical effects of L.S.D. given as a treatment under controlled medical conditions. Possible genetic effects of L.S.D. and other drugs are discussed on the basis of data from laboratory animals and humans. Also discussed are needs for futher research. The necessity to aviod scare techniques in disseminating information about drugs is emphasized. An aprentlix includes seven background papers reprinted from professional journals, and a bibliography of current articles on the possible genetic effects of drugs. (EB) National Clearinghouse for Mental Health Information VA-w. Alb alb !bAm I.S. MOMS Of NAM MON tMAN IONE Of NMI 105 NUNN NU IN WINES UAWAS RCM NIN 01 NUN N ONMININI 01011110 0.
    [Show full text]
  • Psilocybin Mushrooms Fact Sheet
    Psilocybin Mushrooms Fact Sheet January 2017 What are psilocybin, or “magic,” mushrooms? For the next two decades thousands of doses of psilocybin were administered in clinical experiments. Psilocybin is the main ingredient found in several types Psychiatrists, scientists and mental health of psychoactive mushrooms, making it perhaps the professionals considered psychedelics like psilocybin i best-known naturally-occurring psychedelic drug. to be promising treatments as an aid to therapy for a Although psilocybin is considered active at doses broad range of psychiatric diagnoses, including around 3-4 mg, a common dose used in clinical alcoholism, schizophrenia, autism spectrum disorders, ii,iii,iv research settings ranges from 14-30 mg. Its obsessive-compulsive disorder, and depression.xiii effects on the brain are attributed to its active Many more people were also introduced to psilocybin metabolite, psilocin. Psilocybin is most commonly mushrooms and other psychedelics as part of various found in wild or homegrown mushrooms and sold religious or spiritual practices, for mental and either fresh or dried. The most popular species of emotional exploration, or to enhance wellness and psilocybin mushrooms is Psilocybe cubensis, which is creativity.xiv usually taken orally either by eating dried caps and stems or steeped in hot water and drunk as a tea, with Despite this long history and ongoing research into its v a common dose around 1-2.5 grams. therapeutic and medical benefits,xv since 1970 psilocybin and psilocin have been listed in Schedule I of the Controlled Substances Act, the most heavily Scientists and mental health professionals criminalized category for drugs considered to have a consider psychedelics like psilocybin to be “high potential for abuse” and no currently accepted promising treatments as an aid to therapy for a medical use – though when it comes to psilocybin broad range of psychiatric diagnoses.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Tuning Drug Release from Polyoxazoline-Drug Conjugates T ⁎ J
    European Polymer Journal 120 (2019) 109241 Contents lists available at ScienceDirect European Polymer Journal journal homepage: www.elsevier.com/locate/europolj Tuning drug release from polyoxazoline-drug conjugates T ⁎ J. Milton Harrisa, ,1, Michael D. Bentleya, Randall W. Moreaditha, Tacey X. Viegasa,1, Zhihao Fanga, Kunsang Yoona, Rebecca Weimera, Bekir Dizmanb, Lars Nordstiernac a Serina Therapeutics, Inc., 601 Genome Way, Suite 2001, Huntsville, AL 35806, USA2 b Sabanci University, Faculty of Engineering and Natural Sciences, Tuzla, 34956 İstanbul, Turkey2 c Department of Chemistry and Chemical Engineering, Chalmers University of Technology, SE-412 96 Göteborg, Sweden ARTICLE INFO ABSTRACT Keywords: Poly(2-oxazoline)-drug conjugates with drugs attached via releasable linkages are being developed for drug Poly(2-oxazoline) or POZ delivery. Such conjugates with pendent ester linkages that covalently bind drugs to the polymer backbone ex- Poly(2-ethyl-2-oxazoline) or PEOZ hibit significantly slower hydrolytic release rates in plasma than the corresponding PEG- and dextran-drug Pendent drugs conjugates. The slow drug release rates in-vitro of these POZ-drug conjugates contribute to extended in-vivo Degradable ester linkages pharmacokinetic profiles. In some instances, the release kinetics may be relatively sustained and ideal foronce-a- Pharmacokinetics week subcutaneous injection, whereas the native drug by itself may only have an in-vivo half-life of a few hours. Drug delivery Phenolic drugs The origin of this unusual kinetic and pharmacokinetic behavior is proposed here to involve folding of the POZ conjugate such that the relatively hydrophobic drug forms a central core, and the relatively hydrophilic polymer wraps around the core and slows enzymatic attack on the drug-polymer chemical linkage.
    [Show full text]
  • Cannabis, the Endocannabinoid System and Immunity—The Journey from the Bedside to the Bench and Back
    International Journal of Molecular Sciences Review Cannabis, the Endocannabinoid System and Immunity—The Journey from the Bedside to the Bench and Back Osnat Almogi-Hazan * and Reuven Or Laboratory of Immunotherapy and Bone Marrow Transplantation, Hadassah Medical Center, The Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 91120, Israel; [email protected] * Correspondence: [email protected] Received: 21 May 2020; Accepted: 19 June 2020; Published: 23 June 2020 Abstract: The Cannabis plant contains numerous components, including cannabinoids and other active molecules. The phyto-cannabinoid activity is mediated by the endocannabinoid system. Cannabinoids affect the nervous system and play significant roles in the regulation of the immune system. While Cannabis is not yet registered as a drug, the potential of cannabinoid-based medicines for the treatment of various conditions has led many countries to authorize their clinical use. However, the data from basic and medical research dedicated to medical Cannabis is currently limited. A variety of pathological conditions involve dysregulation of the immune system. For example, in cancer, immune surveillance and cancer immuno-editing result in immune tolerance. On the other hand, in autoimmune diseases increased immune activity causes tissue damage. Immuno-modulating therapies can regulate the immune system and therefore the immune-regulatory properties of cannabinoids, suggest their use in the therapy of immune related disorders. In this contemporary review, we discuss the roles of the endocannabinoid system in immunity and explore the emerging data about the effects of cannabinoids on the immune response in different pathologies. In addition, we discuss the complexities of using cannabinoid-based treatments in each of these conditions.
    [Show full text]
  • Downloaded from by Pediatricsguest on October Vol.3, 2021 109 No
    Just a Click Away: Recreational Drug Web Sites on the Internet Paul M. Wax, MD ABSTRACT. The explosive growth of the Internet in sharp rise in MDMA use among college students as recent years has provided a revolutionary new means of well.3 The report of the Drug Abuse Warning Net- interpersonal communication and connectivity. Informa- work released in December 2000 reveals that emer- tion on recreational drugs—once limited to bookstores, gency department (ED) episodes related to MDMA, libraries, mass media, and personal contacts—is now GHB, and ketamine increased significantly during readily available to just about anyone with Internet ac- 4 cess. Not surprising, Internet access greatly facilitates the the period 1994 to 1999. In addition, abuse of some free and easy exchange of ideas, opinions, and unedited older drugs, such as dextromethorphan, seems to be 5 and nonrefereed information about recreational drugs. on the upsurge. This article presents a patient who came to medical at- Simultaneous with this “club” drug revolution has tention as the result of recreational drug-taking behavior been the explosive growth of the Internet. A dra- directly influenced by her Internet browsing. A second matic change in the everyday means of communica- case is presented in which the only information available tions has taken place. E-mail is now ubiquitous, and about the medical effects of a new “designer” drug was the World Wide Web, known as the Internet, brings found on a recreational drug Internet Web site. Several people together from all over the world attracted by such Web sites are described in detail.
    [Show full text]
  • Motivation of an Entheogenic Chemist
    1 (A Brief History and) Motivation of an Entheogenic Chemist Casey William Hardison - POWd (Civ) Abstract Casey Hardison was arrested spring 2004 for the production of psychedelic-type drugs, i.e., LSD, 2C- B and DMT. In the three years since, not one person from ‘authority’ had bothered to ask him what motivated him to synthesise psychedelic drugs. It was as if the a priori assumption that ‘all illegal drugs are bad’ had provided the answer. Hence, the Judge asserted that Hardison did it for “that basest of human emotion, greed” as though the psychospiritual benefits of an alchemical path dedicated to expanding consciousness and personal transformation, through insights integrated into action, upon which he had expounded at great lengths during trial, were some elaborate “portmanteau defence”, just some ruse to get him out of the dock. It was not, it was a committed stand for ‘cognitive liberty’ and for a world full of people who understand the fine line between alone and all one. MINDSET I was born in Washington State on the edge of Western exploration in the New World in the summer of 1971. I came of age in and around the communal rooms of AA, NA, ACA, Alanon and Alateen throughout the Pacific and Mountain West. My father is 33 years sober. His father died 14 years sober in 1982. I too wrestled my psychospiritual demons through alcohol and Cannabis which gratefully led me to the rooms of AA and NA where, at the age of 14, I declared myself an alcoholic and an addict. I delved headlong into the 12 Steps and promptly saw that I had wrapped myself in a shame-bound identity (‘ism’ - internalised shame manifested).
    [Show full text]
  • a Review of LSD Treatment in Alcoholism
    f Int,Pharmecopsychlatry 6, 223-235 (1971). LSD 2369 ............... i J ...... Int. Pharmacopsychiat. 6:223-235 (1971) t I , A Review of LSD Treatment in Alcoholism _ F.S. Abu_zahab, sr. and B.J. Anderson Departments of Psychiatry and Pharmacology, University of Minnesota, Minneapolis, Minn. Abstract. A total of 31 investigations involving 1,105 patients, on the effect of LSD in the treatment of alcoholics are reviewed. There were 13 single large-dose studies without controls, 5 such studies with controls, 4 studies of multiple low-dose LSD without controls, 3 multiple low-dose studies with controls, and 6 miscellaneous investigations that did not fit any of these categories. Single doses ranged between 50 and 800 _g, while multiple doses (maximum of 6 doses). Follow-up ranged from none to 65 months. The overall effectiveness roafnthisged cont(perrovsingleersialdotreatmentse) from 25of talcoholicso 800 _g, remainwith as tdisappointing.otal maximum Itdowases odifficultf 100-6,4to00reacvhg meaningful generalizations from the variety of published investigations with different de- l signs and variant criteria for improvement. The administration of lysergic acid diethylamide (LSD) in alcoholism stems from a pragmatic clinical observation that delirium tremens sometimes scare the alcoholic patient to such a degree that he looks at his problems and decreases his alcoholic intake. Analogously, electroconvulsive therapy is used in psychiatry because some psychotic patients seem to be clinically improved after a seizure. Such reasoning led to the introduction of lysergic acid in the treatment of alcoholics, in 1953, by Hoffer, Osmond and Hubbard. Since that year, several conflicting studies have been published, and 3 books on this controversial treat- ment have appeared (2, 22, 40).
    [Show full text]